SNGX vs SPRB

Soligenix, Inc. vs Spruce Biosciences, Inc. — Valuation Comparison 2026

SNGX

Pharmaceutical Preparations
Soligenix, Inc.
Quality
4.9
out of 10
Value Trap
35
LOW
Price
$0.91
Last close
Models
9/13
Active
VS

SPRB

Pharmaceutical Preparations
Spruce Biosciences, Inc.
Quality
5.3
out of 10
Value Trap
30
LOW
Price
$51.27
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType SNGX Fair ValueSNGX Upside SPRB Fair ValueSPRB Upside
Bayesian DCF Intrinsic $0.30 -67.5% $21.55 -58.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.74 +90.8% $27.57 -46.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SNGX vs SPRB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SNGX vs SPRB — Which Stock Is More Undervalued?

SPRB scores higher with a 5.3/10 quality rating vs SNGX's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Soligenix, Inc. (SNGX) and Spruce Biosciences, Inc. (SPRB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SNGX currently trades at $0.91 with a QOC of 4.9/10, while SPRB trades at $51.27 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).